Purple Biotech Ltd.

符号: PPBT

NASDAQ

0.67

USD

今天的市场价格

-0.6807
市盈率
-0.0254
PEG比率
17.38M
MRK市值
0.00%
DIV收益率

Purple Biotech Ltd. (PPBT) 财务报表

Q: 什么是 Purple Biotech Ltd. (PPBT) 总资产是多少？

Purple Biotech Ltd. (PPBT) 总资产为 .

Download

年度季度

线性对数

在图表中，您可以看到的动态默认数字 Purple Biotech Ltd. (PPBT). 的默认数据。公司收入显示 0.243 M 的平均值，即 -0.171 % 增长率。整个期间的平均毛利润为 0.164 M，即 -0.170 %. 平均毛利率为 0.610 %. 公司去年的净收入增长率为 -0.045 %，等于 -0.325 % % 整个公司历史的平均增长率.,

年度季度

10Y 20Y 30Y 40Y

资产负债表

深入分析 Purple Biotech Ltd. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 -0.189. 在流动资产领域，PPBT 的报告货币为15.788. 这些资产中的很大一部分，即 15.412 是现金和短期投资。与去年的数据相比，该部分的变化率为-0.520%. 公司的长期投资虽然不是其重点，但以报告货币计算的0（如果有的话）为0。这表明与上一报告期相比，0.000% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 0.163. 这一数字表明，-0.318% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 34.207. 这方面的年同比变化率为 -0.271%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为0，存货估值为 0，商誉估值为 28.02（如有. 无形资产总额（如果有）按 0.03 估值.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014
balance-sheet.row.cash-and-short-term-investments	73.01	15.4	32.1	47.2	57.8	6.4	6.7	3.9	14.7	10.6	1.3	0.2
balance-sheet.row.short-term-investments	4.34	0.9	17.1	36.3	46.6	2	1.5	0	7.9	0	0	0
balance-sheet.row.net-receivables	0	0	0	0	0.5	1.5	0.7	0	0.2	0.1	0.4	0
balance-sheet.row.inventory	0	0	0	0	0	-1.5	1	0	-7.8	0	0	0
balance-sheet.row.other-current-assets	3.29	0.4	1.1	1.3	1	1.9	0.1	0.2	7.9	0.1	0	0.1
balance-sheet.row.total-current-assets	76.3	15.8	33.3	48.5	59.3	8.3	8.5	8	14.9	10.8	1.8	0.3
balance-sheet.row.property-plant-equipment-net	2.18	0.5	0.7	0.9	1	0.2	0	0	0	0	0	0
balance-sheet.row.goodwill	112.06	28	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	0.11	0	20.7	20.5	20.5	6.2	6.2	6.2	0	0	0	0
balance-sheet.row.goodwill-and-intangible-assets	112.18	28	20.7	20.5	20.5	6.2	6.2	6.2	0	0	0	0
balance-sheet.row.long-term-investments	0	0	0	0.2	3.1	0	0	0	0	0	0	0
balance-sheet.row.tax-assets	0	0	0	0	-3.1	0	0	0	0	0	0	0
balance-sheet.row.other-non-current-assets	0	0	0	0.2	3.1	0	0	0	0	0	0	0
balance-sheet.row.total-non-current-assets	114.36	28.5	21.4	21.7	24.5	6.4	6.2	6.2	0	0	0	0
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	190.66	44.3	54.6	70.2	83.8	14.7	14.7	14.2	14.9	10.8	1.8	0.3
balance-sheet.row.account-payables	10.15	3.5	2.1	1.5	1.2	1.2	0.7	0.2	0.5	0.4	0.5	0.1
balance-sheet.row.short-term-debt	0.74	0.2	0.2	0.2	0.2	0.2	0	1.7	0	0	0	0
balance-sheet.row.tax-payables	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.long-term-debt-total	0.87	0.2	0.3	0.6	0.7	0	0	0	0	0	0	0
Deferred Revenue Non Current	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	0	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	13.01	3.5	4.7	2.6	1.7	1.1	2.6	2	0.8	0.8	0.5	1.2
balance-sheet.row.total-non-current-liabilities	3.95	2.8	0.5	0.8	1	0.3	0.4	1.5	0.3	0.2	0.5	0.1
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	-0.5	-0.1
balance-sheet.row.capital-lease-obligations	1.42	0.2	0.5	0.7	0.9	0.2	0	0	0	0	0	0
balance-sheet.row.total-liab	27.85	10	7.5	5.1	4.1	3.9	3.7	5.6	1.5	1.4	1	1.3
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.retained-earnings	-520.12	-137.5	-117.6	-95.9	-77.5	-49.5	-43.7	-38.6	-26.2	-14.1	-9.9	-4.6
balance-sheet.row.accumulated-other-comprehensive-income-loss	69.19	38.5	10.1	8.8	8	3.1	1.6	2.5	1.3	1.3	1.3	1
balance-sheet.row.other-total-stockholders-equity	613.23	133.2	154.4	152	148.9	56.9	52.6	43.4	38.2	22.2	9.3	2.7
balance-sheet.row.total-stockholders-equity	162.29	34.2	46.9	64.8	79.4	10.4	10.5	7.3	13.4	9.4	0.8	-0.9
balance-sheet.row.total-liabilities-and-stockholders-equity	190.66	44.3	54.6	70.2	83.8	14.7	14.7	14.2	14.9	10.8	1.8	0.3
balance-sheet.row.minority-interest	0.51	0.1	0.2	0.3	0.4	0.4	0.5	1.3	0	0	0	0
balance-sheet.row.total-equity	162.81	34.3	47.1	65.1	79.8	10.9	11	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	190.66	-	-	-	-	-	-	-	-	-	-	-
Total Investments	4.34	0.9	17.1	36.5	46.6	2	1.5	0	7.9	0	0	0
balance-sheet.row.total-debt	1.61	0.4	0.5	0.7	0.9	0.2	0	0	0	0	0	0
balance-sheet.row.net-debt	-67.07	-14.1	-14.5	-10.1	-10.4	-4.2	-5.2	-3.9	-6.8	-10.6	-1.3	-0.2

现金流量表

在 Purple Biotech Ltd. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 -0.134 的转变。该公司最近通过发行 5.67 扩大了股本，与上一年相比出现了0.000 的差异. 有趣的是，公司的部分股票，特别是 0，是由公司自己回购的。这一举动导致0.000 比上一年有所变化。同时，以报告货币计算，公司的应付账款目前为 1.33. 公司的投资活动产生了现金使用净额，按报告货币计算达到13126000.000. 与上一年相比， -0.341 发生了变化. 在同一时期，公司记录了 0.2, 0 和 -0.17，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将0 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 -0.89，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014
cash-flows.row.net-income	-19.95	-19.9	-21.8	-17.8	-28.1	-5.9	-5.6	-13	-12.1	-4.2	-5.3	-2.6
cash-flows.row.depreciation-and-amortization	0.2	0.2	0.2	0.2	0.2	0.2	0	0	0	0	0	0
cash-flows.row.deferred-income-tax	0.64	-0.8	0	0	0	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	1.88	1.9	2.4	2.1	2.6	1.3	0.8	2.3	0.4	0.1	0.1	0.3
cash-flows.row.change-in-working-capital	0.27	0.3	3.3	0.6	-2.4	0.3	-0.5	0.1	0.3	0.3	-0.1	0.1
cash-flows.row.account-receivables	0	0.2	0.3	-0.3	0.5	0.1	0	0	0	0.2	0	-0.1
cash-flows.row.inventory	0	0	0	0.6	-0.5	-0.1	0	0	0	0.1	0	0.1
cash-flows.row.account-payables	1.33	1.3	0.8	0.3	-2.3	0.5	0.4	-0.5	-0.1	-0.2	0.5	0
cash-flows.row.other-working-capital	-1.06	-1.2	2.1	0	0	-0.2	-0.9	0.6	0.4	0.2	-0.6	0.1
cash-flows.row.other-non-cash-items	-2.9	-0.9	-0.8	-0.1	15.5	-1.5	-3.2	1.9	5.2	0.6	0.8	1.7
cash-flows.row.net-cash-provided-by-operating-activities	-19.86	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	0	0	-0.2	-0.1	-0.2	0	0	0	0	0	0	0
cash-flows.row.acquisitions-net	-3.55	-3.5	0	0	0.1	0	0	-1.7	0	0	0	0
cash-flows.row.purchases-of-investments	0	0	0	0	-49.6	-2.1	0	0	-7.9	0	0	0
cash-flows.row.sales-maturities-of-investments	16.68	16.7	19.8	13.2	0	1.5	0	0	0	0	0	0
cash-flows.row.other-investing-activites	0.67	0	0.3	0.4	0.1	0.2	2.1	4.5	0	0	0	0
cash-flows.row.net-cash-used-for-investing-activites	13.8	13.1	19.9	13.4	-49.6	-0.4	2	2.8	-7.9	0	0	0
cash-flows.row.debt-repayment	-0.17	-0.2	-0.2	-0.2	-0.2	-0.2	0	-0.1	0	-0.3	0	0
cash-flows.row.common-stock-issued	5.86	5.7	1.5	0.6	27.9	2.6	4.7	2.4	6.3	14.9	6.8	0
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	-2.1	0	0
cash-flows.row.dividends-paid	0	0	0	0	0	0	0	0	0	-0.3	0	0
cash-flows.row.other-financing-activites	-0.93	-0.9	-0.2	1.1	40.8	2.8	3.1	0.7	4.1	0.4	-1	0.7
cash-flows.row.net-cash-used-provided-by-financing-activities	5.46	5.5	1.1	1.5	68.5	5.2	7.8	3	10.4	12.6	5.8	0.7
cash-flows.row.effect-of-forex-changes-on-cash	0.05	0.1	-0.2	0	0.1	0	-0.1	0	-0.1	-0.1	-0.2	0
cash-flows.row.net-change-in-cash	-0.54	-0.5	4.1	-0.4	6.9	-0.8	1.2	-2.8	-3.8	9.2	1.1	0.2
cash-flows.row.cash-at-end-of-period	68.68	14.5	15	10.9	11.2	4.4	5.2	3.9	6.8	10.6	1.3	0.2
cash-flows.row.cash-at-beginning-of-period	69.22	15	10.9	11.2	4.4	5.2	3.9	6.8	10.6	1.3	0.2	0
cash-flows.row.operating-cash-flow	-19.86	-19.2	-16.7	-15.1	-12.1	-5.6	-8.5	-8.6	-6.3	-3.3	-4.5	-0.5
cash-flows.row.capital-expenditure	0	0	-0.2	-0.1	-0.2	0	0	0	0	0	0	0
cash-flows.row.free-cash-flow	-19.86	-19.2	-17	-15.2	-12.2	-5.6	-8.5	-8.6	-6.3	-3.3	-4.5	-0.5

利润表行

Purple Biotech Ltd. 的收入与上期相比变化了 1.000%。据报告, PPBT 的毛利润为 -0.2。该公司的营业费用为 22.07，与上年相比变化了 -2.349%. 折旧和摊销费用为 0.2，与上一会计期间相比变化了 -0.830%. 营业费用报告为 22.07，显示-2.349% 的同比变化。销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。基于近期数据的EBITDA为 0，同比增长0.015%. 营业收入为 -22.27，与上年相比变化了-0.015%. 净利润的变化率为 -0.045%。去年的净收入为-19.88.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014
income-statement-row.row.total-revenue	0	0	-0.9	-0.3	1	1	1	0.9	0	0	0	0
income-statement-row.row.cost-of-revenue	0.2	0.2	0.2	0.2	0.2	0	0	0	0	0	0	0
income-statement-row.row.gross-profit	-0.2	-0.2	-1.1	-0.6	0.8	1	1	0.9	0	0	0	0
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	17.03	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	0	0	0	0	-15.7	-0.2	0	0	0	0	0	0
income-statement-row.row.operating-expenses	22.22	22.1	22.6	17.9	13.8	8.8	8.8	12.1	7.2	4.1	5.2	1.2
income-statement-row.row.cost-and-expenses	22.27	22.3	22.6	17.9	13.8	8.8	8.8	12.1	7.2	4.1	5.2	1.2
income-statement-row.row.interest-income	0.47	0.5	1	0.3	0.3	0.2	0.1	0.1	0.1	0.1	0	0
income-statement-row.row.interest-expense	2.19	2.2	0.1	0.2	0.1	0.2	0.6	0	0	0	0	0
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-7.98	2.3	0.8	0.1	-40.7	1.3	2.7	-1	-5.1	-0.1	-0.1	-1.4
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	0	0	0	0	-15.7	-0.2	0	0	0	0	0	0
income-statement-row.row.total-operating-expenses	-7.98	2.3	0.8	0.1	-40.7	1.3	2.7	-1	-5.1	-0.1	-0.1	-1.4
income-statement-row.row.interest-expense	2.19	2.2	0.1	0.2	0.1	0.2	0.6	0	0	0	0	0
income-statement-row.row.depreciation-and-amortization	0.47	0.2	1.2	0.6	-40.6	-0.5	0	0	0	0	-0.1	0
income-statement-row.row.ebitda-caps	-20.96	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-12	-22.3	-22.6	-17.9	12.6	-7.2	-7.8	-12.2	-7.2	-4.1	-5.2	-2.6
income-statement-row.row.income-before-tax	-19.98	-20	-21.8	-17.8	-28.1	-5.9	-5.6	-13	-12.1	-4.2	-5.3	-2.6
income-statement-row.row.income-tax-expense	-9.54	-0.1	-0.9	0.6	-15.7	0.2	-2.6	0	4.9	0.1	0.1	0
income-statement-row.row.net-income	-19.88	-19.9	-20.8	-18.5	-12.4	-6.1	-5.2	-12.3	-12.1	-4.2	-5.3	-2.6